SynCardia Systems Revenue and Competitors
Estimated Revenue & Valuation
- SynCardia Systems's estimated annual revenue is currently $16.3M per year.
- SynCardia Systems received $14.0M in venture funding in December 2013.
- SynCardia Systems's estimated revenue per employee is $155,000
- SynCardia Systems's total funding is $39.4M.
Employee Data
- SynCardia Systems has 105 Employees.
- SynCardia Systems grew their employee count by 35% last year.
SynCardia Systems's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & President | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Clincial Support | Reveal Email/Phone |
4 | Director Global Distribution and Clinical Education | Reveal Email/Phone |
5 | President & Chief Commercial Officer | Reveal Email/Phone |
6 | Director Quality and Regulatory Affairs | Reveal Email/Phone |
7 | Senior Information Technology Manager | Reveal Email/Phone |
8 | CES Production Manager | Reveal Email/Phone |
9 | Sustaining Engineering Manager | Reveal Email/Phone |
10 | Senior Project Manager | Reveal Email/Phone |
SynCardia Systems Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $0.8M | 5 | -29% | N/A | N/A |
#4 | $5.3M | 34 | 0% | N/A | N/A |
#5 | $2.5M | 16 | -20% | N/A | N/A |
#6 | $1.1M | 7 | 0% | N/A | N/A |
#7 | $0.9M | 6 | 0% | N/A | N/A |
#8 | $2.2M | 29 | 21% | $58.2M | N/A |
#9 | $171.9M | 1109 | -3% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is SynCardia Systems?
SynCardia Systems, LLC (www.syncardia.com) in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart (TAH) is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® Portable Driver, which powers the SynCardia TAH and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
keywords:Healthcare,Medical Devices,Pharmaceuticals
$39.4M
Total Funding
105
Number of Employees
$16.3M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SynCardia Systems News
The major players covered in Heart Transplant Markets: SynCardia Systems; HeartWare International; Calon Cardio; Optum; Apaxis Medical; Carmat...
Thoratec Corporation, SynCardia Systems, Cirtec Medical Systems, BiVACOR, MyLVAD, CARMAT, Jarvik Heart, Abbott, AbioMed, Cleveland Heart.
Leading Manufacturers Analysis in Global Artificial Heart Market 2022: ? SynCardia Systems, BiVACOR, CARMAT, Abbott, Cleveland Heart, AbioMed,...
The workings of Syncardia’s CardioWest heart are actually outlined nicely by NIH: A TAH usually extends life for months beyond what is expected with end-stage heart failure. If you’re waiting for a heart transplant, a TAH can keep you alive while you wait for a donor heart. A TAH also can impro ...
TUCSON, Ariz. — The Freedom portable driver received FDA approval on June 26, 2014 for use with the SynCardia temporary Total Artificial Heart as a bridge to transplantation in cardiac transplant candidates who are clinically stable. Watch the story of two SynCardia Total Artificial Heart patie ...
Other Companies in Tucson
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 105 | -1% | N/A |
#2 | $22.1M | 105 | 3% | N/A |
#3 | $26.2M | 107 | 14% | N/A |
#4 | $22.9M | 109 | 5% | N/A |
#5 | $19.8M | 110 | 8% | N/A |
SynCardia Systems Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2004-05-25 | $3.7M | B | Article | |
| 2009-06-25 | $10.3M | D | Highway 12 Ventures | Article |
| 2013-03-21 | $19.0M | Undisclosed | Athyrium Opportunities Fund | Article |
| 2013-12-18 | $14.0M | Undisclosed | Wedbush PacGrow Life Sciences | Article |